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The annual incidence of head and neck squamous cell cancer (HNSCC)  
is about 680,000 new cases in the world, with a crude rate of 9.7 per 100,000 persons 
and a cumulative risk of 1.06 (1). Options such as radiation therapy (RT) alone or with 
concomitant chemoradiation therapy (CRT) plays a significant role in the curative 
treatment of locally advanced disease (stages III-IV). 
F-18 fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is one of the 
most widely used tracer in positron emission tomography (PET) studies in oncology. 
Quantification of tracer uptake can be carried out in diverse ways, from visual analysis 
to a simple calculation of fluorodeoxyglucose (FDG) uptake level for example, the 
standardized uptake value (SUV) and by more complicated analyses, calculating the 
metabolic variation with time (metabolic rate) of FDG uptake. 
In the management of HNSCC patients, functional imaging performed with 18F-FDG 
PET-computed tomography (CT) has several applications (2). F-18 FDG PET-CT is 
endorsed by the National Comprehensive Cancer Network (NCCN) guidelines for 
diagnosis and staging (3). F-18 FDG PET-CT can identify an occult primary tumour 
(4) and is very accurate in detecting metastases or second primary tumours elsewhere 
in the body (2). Accurate delineation of target volumes is critical for intensity 
modulated radiation therapy (IMRT) treatments.  
The response of HNSCC to treatment depends on many factors such as clinical history 
(previous treatments), tumour characteristics (stage and biology), surrounding 
microenvironment, and host immunoresponse.  
Numerous studies have confirmed the role of predictive molecular biomarkers such as 
p16 expression (surrogate of human papilloma virus status in oropharyngeal cancer) 
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or epidermal growth factor receptor expression (5). The role of imaging-based 
biomarkers has been explored too, but none of them can be used routinely to improve 
the selection of responders before the start of or during treatment (6–10). 
It has been well-known that 18F-FDG PET-CT plays a significant role in the 
assessment of the response after CRT or RT alone. The pre-eminence of functional 
over conventional imaging in response evaluation consists of its ability to 
semiquantitatively assess glucose uptake as a cancer cell viability indicator. PET-CT 
has shown high negative predictive value (NPV) if performed at least 8 to 16 weeks 
after completion of treatment (11,12). After concurrent CRT for locally advanced 
HNSCC, locoregional recurrence develops in 20% to 30% of patients, typically in the 
gross tumour volume, suggesting that dose escalation or additional interventions could 
help in improving local tumour control. FDG PET-CT might be used to identify the 
biological target volume (BTV) inside the target volume. Evidence exists that local 
recurrences characteristically occur within areas of high FDG uptake (13). 
Such areas could be treated with a boost dose using IMRT techniques to reduce the 
risk of recurrence. In recent years, there has been increasing interest in the role of 
18F-FDG PET-CT acquired during CRT, defined as ad interim FDG PET (PETint), 
with the aim to identify tumour responsiveness at an early stage of treatment (14). 
Early identification of poor responders or nonresponders may allow modification of 
the treatment plan (volume and doses) and/or implementation of alternative 
therapeutic strategies to intensify treatment. Few data are available on at least two 
18F-FDG PET-CT scans over the whole RT course to evaluate changes in FDG 
uptake in the primary tumour as well as lymph node metastases (15,16). The aim of 
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this intensive monitoring during the treatment would also be to adjust the treatment 
plan according to the change in tumour volume in response to RT (adaptive RT) (17). 
This study had the following aim and objectives. 
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Aim: To assess response evaluation of nodal status in post treatment 18F-FDG-
PET-CT scans in HNSCC using a 5-point Likert scale (Deauville score (DS)). 
Objectives: 
1. To assign Likert scale (Deauville criteria score (DS)) and SUVmax to all 
follow up PET scans 
2. To determine whether interpretation of follow up PET scans can be improved 
3. To categorise as responders vs non-responders  
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A. Positron Emission Tomography  
1. Principles of F-18 and FDG Production - Positron Emission Tomography 
(PET) is a nuclear imaging modality which enables studies of the uptake and 
metabolism of a positron emitting radionuclide. These can be visualized and 
quantified. Those which have protons excess have two modes of decay - by 
electron capture (EC) or positron decay. PET scanner cannot image isotopes 
undergoing EC. PET imaging uses radioactive substances such as Fluorine-18, 
Carbon-11, and Oxygen-15 which are positron emitters. Fluorine, 18F is the 
most common radionuclide in oncologic imaging, the generation of which 
happens by a powerful accelerator 
called as cyclotron. In this 
accelerator the protons are 
accelerated and merged with 18-
Oxygen (18O) that simultaneously 
evaporates a neutron. 
The half-life of 18F is 110 
minutes. It decays in the following 
manner: 
 
 
(where is a positron, ν is a neutrino). 
 
Figure 1: Production of F18. Calif: Crump Institute 
for Molecular Imaging, University of California, 
1994–2003 
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PET facilities therefore need a certain proximity to the cyclotron site where the tracer 
is produced. 18F, as an unstable radionuclide, is attached to deoxyglucose to produce 
2-deoxy-2-FDG (glucose analogue). 
Emission of positron from 18F causes it return to a stable 18O nuclide. After 
travelling few millimetres, positron collides with several electrons and loses energy. 
Annihilation phenomenon is produced by colliding with yet another electron almost at 
rest. The mass of the positron and electron is extinguished In this process and two 
photons of 511keV are produced, travelling in equal and opposite directions (180° 
angle). Coincidence occurs in a PET camera, when photons that are opposite to each 
other and simultaneously, hit the detectors are registered in the gamma detectors and a 
line can be traced along which the positron decay occurred in tissue. 
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1. Coincidence detection - The nearly back-to-back two gamma rays is the key 
to PET. The detectors are made of crystals which have high atomic numbers 
and densities; for example, bismuth germinate (BGO), cerium-doped 
gadolinium silicate (GSO) or cerium doped lutetium oxyorthosilicate (LSO). 
For 511 keV photons, the coincidence detection efficiency for 25 mm LSO or 
BGO crystals is approximately 
80%. 
There is a likelihood that event of 
annihilation must have straight 
line between the two detectors, if 
two detectors which are placed on opposite sides of the patient record an event 
at nearly the same time. Two detectors are said to be “in coincidence” when the 
events are detected by camera at almost the same time in both detectors. The 
key to PET images his ability to identify these coincident events is (18). This 
“electronic collimation” through coincidence detection makes PET more 
efficient than other nuclear medicine studies. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Coincidence detection 
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Coincidence imaging. 
The photons emitted by annihilation 
points A and C are in coincidence, but 
the distances they will travel before they 
reach the scintillation crystals are 
different. There is a predetermined time 
window within which detected photons 
are considered to be in coincidence. 
Therefore, even though photons a and a1 
and c and c1 are coincident, they will be 
electronically rejected as non-coincident. 
However, the coincident photons from 
point B are likely to reach the 
scintillation crystals within the time 
window and will be accepted as 
coincident. Kapoor et al, 2004 
 
 
 
Figure 3: Coincidence 
imaging 
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2. Tumour and FDG metabolism - Glucose is transferred into cells by 
facilitative glucose transporters (GLUT) proteins. There are known 13 isoforms 
of GLUT holding different affinities for hexoses. Overexpression of GLUTs, 
especially GLUT1 happens early in many types of malignant transformation 
which reflects an increased glucose demand in tumour cells (19). In the start of 
the 20th century, biochemist Otto Warburg, described how glucose is avidly 
consumed by cancer cells and produce lactic acid even under aerobic 
conditions which was called the Warburg effect, also identified as aerobic 
glycolysis (20). This shift to aerobic glycolysis is probably multifactorial and 
Ngo et al explains it in the following manner. Cancer cells releases lactate 
which is beneficial for the microenvironment and helps in tumour growth and 
probability of metastasis. Furthermore, with a less involved oxidative pathway, 
the amount of reactive oxygen species is reduced that influences cellular 
activities affecting apoptosis. Another reason is that the generation of biomass 
instead of energy is important if the proliferative capacity is to be maintained 
(21). In glycolysis there is a ten-step pathway in which one glucose molecule is 
converted into two pyruvate molecules, two ATP and two reduced 
nicotinamide adenine dinucleotide, NADH. In the presence of oxygen, 
pyruvate can be further metabolized to acetyl-CoA which is a major fuel for the 
citric acid cycle. In anaerobic condition, in cells that lack mitochondria or if a 
Warburg effect is present, pyruvate is reduced to lactate that is a less efficient 
pathway in terms of generating ATP (22) (fig 4). The augmented urge for 
glucose, the increased glycolysis in cancer cells as compared with normal 
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tissue is a prerequisite for PET. FDG uptake in the cells occurs by the same 
GLUTs, as glucose. They also share the primary glycolytic step, a 
phosphorylation, catalysed by hexokinase. Unlike glucose-6-phosphate, 
phosphorylated FDG is not further metabolized and being a polar molecule 
becomes trapped in the cell.  
Figure 4 Aerobic glycolysis occurring in the cytosol of the 
cell with a net gain of 2 ATP molecules. 
22 
 
 
 
During the accumulation phase extra glucose demanding cells will accumulate 
more FDG compared with normal cells and this relative difference in FDG 
accumulation will show uptake on the PET scan (fig 5). The fact that the 
amount of FDG uptake is correlated with the glucose demand is of very 
essential value in oncologic imaging and therefore tumour viability. 
 
Figure 5 Relative difference in FDG accumulation between tumour cells and normal cells will be 
revealed on PET-CT imaging. 
Sjövall, et. al (2015). PET in the evaluation of head and neck cancer treatment - management of 
the neck, Otorhinolaryngology, Lund University 
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1. PET development - The first images using annihilation radiation following 
positron emission were produced in the early 50’s, initially attempting to pick 
up brain tumours. This application had a simple probe and two opposed 
coincidence detectors. It was in the middle of 1970s that more powerful 
cyclotrons, producing isotopes including 11C, 13N, 15O and 18F became 
widely available. 18F-FDG was first produced in 1978. A concurrent technical 
development to more sensitive and sophisticated detection devices ultimately 
resulted in high resolution images acquired from multiple small detectors 
placed in a circle around the positron-emitting subject. The resolution of 
modern PET cameras in clinical use is approximately 5mm. Compared to CT 
or MRI the spatial resolution in PET is poor. In order to obtain structural 
correlation and attenuation correction, modern PET cameras are integrated with 
CT scanners (and recently also, MRI scanners). These dual modality systems 
can automatically fuse both functional and structural images. 
This is remarkable since studies published ten years ago or more usually refer 
to PET as single PET studies but currently, as in this study, PET implies PET-
CT. PET is combined with a contrast enhanced CT for attenuation correction 
and anatomic localization. 
In staging procedures (23) as well as for distinguishing a benign versus 
malignant character of a lesion (24), PET-CT is better than solitary CT or PET. 
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Imaging procedure - PET studies are performed after a four to six hour fasting 
period. This is because FDG competes with endogenous glucose for uptake into 
the cells and the FDG uptake in tumour cells can be reduced by increased 
serum glucose levels (25). In addition, another factor which disturbs the image 
quality is meal associated insulin secretion which can cause a diffuse muscular 
FDG uptake (26). The blood glucose is then measured and should be <150 
mg/dl. If the blood glucose is higher, the patient is scheduled at a later date. 
After an intravenous injection of FDG, with a dose of 3.7 MBq/kg body weight 
to maximum 370 MBq, the patient rests for the forty-five minutes to one-hour 
uptake period. The scan time for acquired images is two minutes per bed 
position. CT scan is performed initially, on free breathing and at low amperage 
dose. This CT scan provides an attenuation map in order to correct PET 
images, which is actually a distribution map of attenuation coefficients 
measured by CT and helps to obtain more legible PET images, thereby 
allowing fusion of PET and CT images (27). 
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2. Assessment of PET scans - Most publications regarding PET-CT in HNSCC 
have been dealing with response to treatment assessment. Conventionally, in 
1980s according to the World Health Organization response evaluation criteria 
and from 2000 according to Response Evaluation Criteria in Solid Tumours 
(RECIST), the tumour response is measured by tumour shrinkage (28). In 
bulky tumours especially, the tumour shrinkage occurs later than the metabolic 
response and this will occur even if minor clones of resistant tumour cells are 
present which make evaluation of the metabolic response in these scenarios 
valuable. In view of the status of PET technique in 1999, European 
Organization for Research and Treatment (EORTC) PET study group brought 
out a paper with recommendations on how to measure FDG uptake for tumour 
response monitoring (22). During that time integrated PET and CT scanners 
were yet to be integrated. Based on the EORTC paper, Wahl et al in 2009 
summarized the present status, recent studies and an update on RECIST and 
they introduced PET Response Criteria in Solid Tumours (PERCIST) (29). 
PERCIST wass intended to be used in clinical trials and in structured 
quantitative reporting of PET results but it is not widely used. Several 
technical, physical and biological factors influence the PET outcome. Though 
they have a relatively small effect, the accumulation of small errors can lead to 
substantial differences in outcome. The most common factors influencing PET 
assessment according to Boellard include camera related factors such as 
relative calibration and incorrect harmonization of clocks between camera and 
dose calibrator. Other technical issues are remaining FDG activity in syringe, 
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wrong time interval for decay correction, scan acquisition, image 
reconstruction limits and the determination of region of interest (ROI). 
Biologic factors relate to the blood glucose level, the accumulation phase, 
inflammatory changes, the comfort of patients, motion and breathing (30). 
a. Quantitative assessment – In this analysis, a ROI encompassing the tumour is 
drawn manually or by software solutions. The amount of radioactivity within 
this ROI is measured.  
b. Semiquantitative assessment - Standardized uptake value (SUV) is called a 
semiquantitative measurement of activity in a region at a fixed time point. SUV 
relates tissue activity to injected activity and the body mass (or area) of the 
patient. 
SUV = mean regional activity (Bq / mL) 
injected activity (Bq) / body weight (g) 
This is one of the most widely used method of calculating FDG uptake in PET. 
In the SUV measurement the body weight is also a factor to be considered. 
Another factor is the plasma activity of FDG that is assumed to be steady. 
Various types of SUV methods are used, the most common are: 
•  SUVmax, the highest single pixel/voxel value and the most frequently used 
parameter 
• SUVmean, the mean SUV value of a number of voxels in a volume of 
interest.  
    •  SUVpeak, the average SUV within a small, fixed-sized ROI, centred on a 
high uptake part of the tumour 
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The type of SUV method to be selected depends on whether the metabolically most 
active portion of the tumour is more important or the total tumour volume? Or are 
they equally important? Vanderhoek et al have analysed tumour response with these 
different types of SUV methods. On average, a 20% variation of individual tumour 
response was noted (ranging up to 90%). The tumours ending up in different 
categories of response were found to be more than 80% when different SUV methods 
were used (31). 
Using SUV as outcome, with the PERCIST criteria comparison of different studies is 
still difficult because of the different parameters and the different formulas used for 
calculation. 
In a clinical setting, SUV may not give additional information to a visual 
evaluation and cannot replace, but might support, the nuclear physician in the 
interpretation of PET images. 
Other parameters based on SUV are metabolic tumour volume (MTV) and total 
lesion glycolysis (TLG), also called SUVtotal. Both of them help in prognosis and are 
used as biomarkers of therapeutic response (32). Different methods with 
various thresholds can be used to find out MTV and no absolute standard is 
standardised. On pre-treatment scans MTV has a higher prognostic value than 
SUVmax (32). TLG combines both metabolic and anatomic data and the total tumour 
burden in the patient is found out according to the formula SUVmean x MTV. 
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c. Qualitative assessment - In this assessment, the distribution and intensity of the 
FDG uptake in suspected tumour foci are compared with the uptake in normal 
structures such as surrounding tissue, brain, mediastinal blood pool and liver. 
For a good qualitative interpretation, it requires clinical experience, knowledge 
of normal distribution and artefacts as well as awareness of expected disease 
pattern. Qualitative assessment usually ends up in either of these three 
categories: positive/indicative for tumour, negative/not indicative for tumour or 
equivocal. The data on reproducibility of qualitative assessment is scarce. A 
Likert scale helps to improve qualitative assessments and PET reports. A 5-
point Likert scale, the Deauville criteria, is validated for lymphoma studies and 
the concordance between readers is good (33). 
Recently the Hopkins criteria was introduced for head and neck cancer, that 
also shows substantial inter-reader reliability (34). 
 
 
 
 
 
 
Table 1 The Deauville criteria and interpretation into categories regarding the neck node response to 
treatment  
Sjövall, J. (2015). PET in the evaluation of head and neck cancer treatment - management of the neck, Otorhinolaryngology, 
Lund University 
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B. Head and neck cancer 
 
Head and neck cancers have taken a great toll of lives among other cancers in 
developing countries across the globe. In India, HNSCC’s have been a significant 
problem constituting approximately one-third of all cancer cases. On the other hand, 
in the developed world it constituted only 4–5% (35). Upto 95% of the carcinomas 
affected mucosal linings of the upper aerodigestive tract and they involved the lip, oral 
cavity, nasal cavity, paranasal sinuses, pharynx, and larynx. The accurate staging at 
diagnosis optimised treatment planning with improved outcomes.  
 
18F-FDG PET-CT has shown significant value at diagnosis for accurate staging, 
prompt planning of treatment, and prognostication of many different types of cancer, 
including HNSCC. More importantly, it also helps in long term surveillance after 
definitive therapy for assessing response.  
However, the poor spatial resolution of PET and the lack of anatomic landmarks can 
make precise localization of disease difficult. In addition, normal anatomic structures 
may show variable FDG uptake causing errors in interpretation. As a result, combined 
PET-CT scanners have become available that allow for both structural and functional 
characterization of disease at the same time (36). There is improved localization of 
abnormalities, better differentiation of therapeutic changes for residual disease, and 
improved assessment of extent of tumour. 
 Hence PET-CT has transformed the staging and surveillance of patients with 
HNSCC by allowing further accurate staging, more focussed treatment modalities, 
prior detection of recurrent disease, and identification of incurable disease to avoid 
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overtreatment. Besides, the combined modality has improved the confidence of 
radiologists (2).  
Functional imaging with 18F-FDG PET-CT have been used to improve 
characterization of both primary tumours and metastatic cancer.  
 
 
Chemoradiotherapy (CRT) has turned out to be a backbone of primary treatment in 
patients with HNSCC because it provides higher response rates than RT alone. 
Negative 18F-FDG PET or PET-CT findings after concurrent CRT have a high 
negative predictive value (NPV) (95%) (37,38). Therefore, in many centres, CRT has 
become the favoured first line of treatment for several types of HNSCC, especially of 
the base of the tongue, tonsil, larynx and hypopharynx. FDG PET-CT is highly 
sensitive (>95%), for identifying malignancy in the head and neck region (39). 
 
Fig. 6 False-positive PET suggests nodal disease. (A) Axial PET image is worrisome for left Zone II lymphadenopathy (arrow). (B) Fused 
PET/CT image correctly localizes the FDG uptake to the submandibular gland, avoiding a false-positive interpretation. 
Agarwal V, Branstetter BF, Johnson JT. Indications for PET/CT in the Head and Neck. Otolaryngol Clin North Am. 2008 Feb;41(1):23–49 
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 The main indication of 18F-FDG PET-CT in newly diagnosed HNSCCs is FDG avid 
cervical lymph node detection, which is one of the most important prognostic factors. 
18F-FDG PET-CT is particularly useful for staging, restaging, RT planning and 
assessment of treatment response in HNSCC patients, due to its superior accuracy 
over clinical examination and conventional anatomic imaging (40).  
Goerres and colleagues (41) showed that PET-CT found distant metastases or second 
primaries in 24% of their patients newly diagnosed with SCC of oral cavity initially 
screened by clinical exam, CT, and chest x-ray. Similarly, Ha and colleagues (42) 
found that the TNM score was altered in 31% of their patients with previously 
untreated HNSCC initially staged with CT or MRI. PET-CT allows for better 
characterization of equivocal abnormalities on CT by PET and for more accurate 
anatomic localization of abnormalities on PET by CT (43). PET-CT is the modality of 
choice for staging of patients with advanced HNSCC with superior sensitivity than 
conventional modalities for the detection of metastases. 
 
1. Staging in HNSCC 
The tumour-node-metastasis (TNM) staging system of the American Joint Committee 
on Cancer is most commonly used to prognosticate and guide therapy for HNSCC. 
(44) 
In a study done by Rhode. et al, in total, 307 patients with histologically 
verified HNSCC were included. Use of PET-CT significantly altered the stratification 
of tumour stage when compared with either chest x-ray plus head and neck 
MRI (CXR/MRI) or chest CT plus head and neck MRI (CCT/MRI) (χ2, P < 0.001 for 
both). Cancer stages based on PET-CT, but not CXR/MRI or CCT/MRI, were 
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associated with significant differences in mortality risk on Kaplan-Meier analyses (P ≤ 
0.002 for all PET-CT-based comparisons). Furthermore, overall discriminative ability 
was significantly greater for PET-CT (C-index, 0.712) than for CXR/MRI (C-index, 
0.675; P = 0.04) or CCT/MRI (C-index, 0.657; P = 0.02) (45). 
FDG PET-CT is a valuable imaging tool for identifying unknown primary tumours in 
patients with known cervical node metastases leading to management change and is 
the standard of care for the initial staging of stage III and IV HNSCCs, for assessing 
therapy response when performed at least 12 weeks after CRT, and for avoiding 
unnecessary planned neck dissection. Irrespective of the size of residual neck nodes, 
neck dissection is evaded if PET-CT findings are negative because survival outcomes 
are not compromised. FDG PET-CT helps in detecting recurrences and metastases 
during follow-up when suspected because of clinical symptoms and is also a 
prognostic marker for patient survival outcomes, for 5 years. Using FDG PET-CT for 
routine surveillance of HNSCC after 6 months of treatment without any clinical 
suspicion should be discouraged (46). 
Diagnosing an unknown primary tumour, identifying regional lymph node 
involvement and distant metastases, and providing prognostic information are the 
major clinical applications of this method. Other used of FDG PET-CT are for precise 
delineation of the tumour volume for RT planning and dose painting, and for 
treatment response monitoring, by detecting residual or recurrent disease (47). 
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2. Utility of 18-FDG PET-CT in Staging 
T Staging 
The T component in the TNM staging system is built on primary tumour size and 
extent of local disease involvement, which varies for various regions in head and 
neck. 
Krabbe and colleagues (48) reported that sensitivity and specificity of FDG PET-CT 
for detecting primary tumour are greater than 90%. Due to the spatial resolution of  
PET, small lesions (few millimetres) may not be detected, especially along superficial 
mucosal surfaces (49), which is compounded by physiologic FDG uptake in the head 
and neck by lymphoid tissues in Waldeyer’s ring, vocal cords, and muscles. In 
addition, necrotic primary tumours may not show FDG uptake above background 
(Fig. 5) (50). In these situations, contrast-enhanced PET-CT can especially be useful 
for augmenting diagnostic accuracy by distinguishing normal muscles and other 
anatomic structures from pathologic cystic and necrotic tumours. 
 
 
 
Fig. 7 False-negative CT overlooks nodal disease. (A) On axial unenhanced CT, the 4-mm lymph node (arrow) 
is too small to be suspicious by size criteria alone. Tiny calcific foci and a rounded configuration are clues to 
the true diagnosis. (B) Increased FDG uptake (arrow) correctly suggests malignancy (metastatic papillary 
thyroid carcinoma). 
Agarwal V, Branstetter BF, Johnson JT. Indications for PET/CT in the Head and Neck. Otolaryngol Clin North Am. 2008 
Feb;41(1):23–49 
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N staging 
The N component in TNM staging system refers to the metastatic regional lymph 
nodes, among the most significant prognostic factors in HNSCC with the presence, 
location and size of the node being important factors (16). Survival decreases to upto 
62% in patients with positive nodes, which underscores the importance of accurate 
nodal staging (51).                                    
Ryu et.al in their prospective study found that PET-CT changed the clinical workup 
(CWU) based TNM classification of 83 lesions in 79 (31.9%) patients; in two patients, 
both T and N changed. In the remaining two patients, both N and M changed. In the 
remaining 169 (68.1%) patients, PET-CT and CWU findings presented similar TNM 
classification. Of the 79 patients with discordant TNM classification, histopathology 
was available in 68 (86.0%). In another three patients, the TNM classification was 
confirmed either by subsequent imaging and clinical follow-up. It was not possible to 
definitively confirm the stage in the remaining eight patients. These cases were not 
included when comparing the PET-CT stage and CWU stage in terms of diagnostic 
accuracy (52). 
Detection of distant metastasis 
Overall incidence of distant metastasis in HNSCC is dependent on the stage of 
disease, particularly the nodal stage. Overall, it is relatively low with a range of 2 – 
18% but tends to be higher with primaries of hypopharynx and nasopharynx (53).  
Therefore, screening for distant metastasis, is generally limited to patients with 
advanced disease, particularly advanced nodal staging or extension towards the 
thoracic inlet.  
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The following is a list of subdivisions of patients with HNSCC in whom screening for 
distant metastases would be specified (54). 
• ≥ 4 lymph nodes metastases 
• Bilateral lymph node metastases 
• Metastatic lymph node size ≥ 6 cm 
• Zone IV lymph node metastases 
• Recurrent HNSCC 
• Second primary tumour 
As lungs are the most common site of metastasis, patients with high risk HNSCC are 
usually staged with CT chest, which is generally more sensitive than PET for very 
small pulmonary lesions due to the high contrast between aerated lung and solid 
metastases. However, when nodules of uncertain causation are identified, PET can 
help to find out those that are around 10mm or larger in size. Nevertheless, as with 
nodal involvement, no imaging technique is currently available to spot microscopic 
disease. This point is illustrated by a study that demonstrated that on clinical follow up 
of patients who had no evidence of distant metastasis on staging CT chest, 11% 
developed distant metastases within 12 months after curative treatment without 
evidence of loco-regional relapse, presumably from previously occult metastatic 
disease. 
Numerous studies have, however, been performed to assess the sensitivity of PET-CT 
in the detection of distant metastasis for HNSCC. In a recently published prospective 
study, 34 patients with previously untreated HNSCC underwent staging PET as well 
as other standard staging investigations (55). Compared with staging CT chest, PET 
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was correctly able to identify previously unrecognized metastases in 6% of the 
patients, all of which were extra-thoracic. Ng et al. compared the use of PET with 
extended field CT (from base of skull to lower abdomen), and they found that 
sensitivity in detecting distant metastases was 76.9% for PET, and 50% for CT 
(P=0.039) (56). The overall sensitivity increased to 80.8% if PET and CT were 
compared side by side. The enhancement in detection of distant sites of disease by 
PET led to alteration of treatment in 13.1% of patients, and a significant difference in 
survival rates was observed between positive and negative scans. 
 
3. Radiotherapy planning 
Molecular imaging with 18F-FDG provides a unique opportunity for RT planning in 
HNSCCs in terms of selection and delineation of target volumes as well as dose 
planning (57). Looking at target volume selection, the additional value of 18F-FDG 
PET-CT is finding occult primary tumour in patients with cervical lymph node 
metastasis with the possibility of decreasing the RT target volume, and consequently 
the acute and late side effects of RT, as well as detection of distant metastases with 
high sensitivity (58). For precise delineation of target volumes and organs at risk, the 
goal of using molecular imaging is to augment the treatment plan thanks to its superior 
sensitivity and contrast resolution over anatomical imaging techniques (59). In the 
initial experience of Daisne et al., gross tumour volume (GTV) demarcated from 18F-
FDG PET was closest to the pathologic GTV from surgical specimens, and 
significantly smaller than GTV delineated by CT and MRI (60). However, subsequent 
data were less consistent (59). The main disadvantage is the lack of a standardized 
method for functional volume segmentation, which heavily influences the volume and 
37 
 
shape of the resulting GTV. Further applications of 18F-FDG PET-CT for RT 
planning are under clinical investigation, and include the likelihood of directing dose 
escalation to 18F-FDG-avid sub-volumes of the tumour as well as adapting the RT 
plan during treatment which comes from the information on the biological and 
molecular tumour changes induced by therapy (59,61–63). 
Moreover, the possibility of targeting radiation-resistant regions within the tumour on 
the basis of biologic information of molecular imaging is under investigation, for 
example the identification of the hypoxic volume within the GTV by using hypoxia-
related PET tracers to deliver higher doses to hypoxic cells (63). 
 
4. Neck Dissection 
Spread by the lymphatics has been shown in HNSCC and in a fairly predictable 
manner (64). However, this rationale is recently interrogated in a subgroup of patients 
with p16-positive tumours where a haematogenous spread of tumour cells is suggested 
as the pattern of distant metastasis (65). 
 
The lymphatic spread has been recognized from the 19th century when the first 
surgical lymphadenectomies, ND, were described (66). The anatomy of the neck is 
divided into six different neck node levels (some refer the superior mediastinal nodes 
caudal to the suprasternal notch but cranial to the innominate artery to a seventh 
level). Level I, II and V are subdivided into “a” and “b” (67) (fig 6). 
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The degree of the ND depends on several variables: the location of the primary 
tumour, lymph node metastases, the risk of microscopic/occult 
disease and whether staging or curative procedure is required. The ND procedure is 
performed for a few hours under general anaesthesia, followed by few days of 
hospitalization. 
Consequences of neck dissections 
A ND with clear margins is a safe procedure with decent therapeutic outcome but can 
be associated with a high rate of morbidity. A thorough assessment before the 
operation is essential in order to avoid cardiovascular events linked with anaesthesia 
as risk factors for HNSCC includes smoking and drinking which also contributes to 
comorbidities. 
It is important to prepare for a safe airway during induction of anaesthesia because the 
primary tumour itself and/or given RT might alter the upper airway anatomy and 
induce trismus. 
Fig 8. Classification of cervical nodal levels (Consensus statement on the classification and 
terminology of neck dissection. Arch Otolaryngol Head Neck Surg 2008; 134: 536–8). 
39 
 
Although uncommon, intra- or postoperative bleeding, infection, chylous fistulas and 
flap necrosis can occur as immediate surgical complications. Also a partly temporary 
facial and/or submental oedema maybe be expected after the procedure. The ensuing 
scarring and sometimes altered contour of the neck, can be apparent as a cosmetic 
problem. 
Numerous cutaneous sensory nerves are per se sacrificed during a ND and can 
sometimes lead to persistent, dull neck pain. Depending on the tumour location, other 
nerves might also be sacrificed or accidentally injured. Lower lip weakness is 
produced by injury to the facial nerve (marginal branch) and Horner syndrome may be 
seen due to sacrificing of the cervical sympathetic chain. Severe dysphagia may be 
caused by bilateral hypoglossal nerve damage but unilateral resection is usually well 
tolerated in that aspect. 
A winged scapula, a shoulder droop, a reduced range of movement and a dull pain 
occurs due to injury to the accessory nerve that causes shoulder weakening and is one 
of the most common nerve damaged. Even if a functional or selective ND is 
performed, the sheer manipulation to keep the accessory nerve intact, sometimes 
seems to disturb the nerve or nerve compression might be caused by postoperative 
related fibrosis. (68,69). 
 
Dysphagia, a sequela usually ascribed to RT, is recently associated with ND as well. 
ND increases the risk to 4-folds of feeding tube dependency 18 months after surgery 
compared with RT or CRT alone (70). There is chance of aspiration due to dysphagia. 
Silent aspiration is lately shown to be more common in patients that have had a ND 
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after RT than those who had undergone operation (p=0.013, Lindblom et al, 
unpublished data). Injured sensory fibres from the vagal nerve might be one of the 
causes of a reduced sensibility in the supraglottic and glottic regions. 
It has been reported by Donatelli Lassig et al that quality of life one year after CRT in 
combination with ND compared with CRT alone does not differ significantly, as 
measured by Short Form Health Survey (SF-36). The ND group only reported greater 
levels of pain (71). 
On the other hand, Eickmeyer et al, have observed 5-year survivors after HNSCC 
treatment. Diverse quality of life parameters were addressed as well as 
measurement of shoulder mobility. A significant adverse long-term effect on shoulder 
mobility was noted and even worse if the accessory nerve was sacrificed. A ND also 
had undesirable impact on activity in general, speech and eating in public (72). This 
has caused a debate whether planned ND following CRT with curative intent is 
required. 
5. Treatment response assessment 
An accurate response evaluation is essential in the management of patients with 
HNSCC treated with CRT. 18F-FDG PET-CT is commonly used to assess treatment 
response, since it detects viable tumour within residual masses, thus overcoming the 
known drawbacks of morphological imaging modalities. In particular, 18F-FDG PET-
CT has a high NPV (> 95%) that spares the patient of needless diagnostic invasive 
procedures and neck dissection in many cases (about 75%), with a significant effect 
on patient outcome and morbidity, and low risk of under-treatment (about 2%)(73) 
Early detection of residual or recurrent disease following RT is a diagnostic challenge 
due to post-treatment anatomical distortions, mostly related to oedema and fibrosis 
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(74). Correctly identifying patients requiring salvage-tailored treatments is the key 
role of a diagnostic tool evaluating treatment efficacy. Moreover, an early detection of 
relapse could help in the selection of patients who could be successfully retreated (75). 
In this setting, 18F-FDG-PET-CT is an exciting modality to evaluate response to 
treatment, as it can assess metabolic activity-rendering malignant process. 
PET/ CT staging has a prognostic role in HNSCC. PET-CT staging separated the 
hazard ratios for both progression free survival (PFS) and overall survival (OS) better 
than CWU staging, regardless of which treatment was employed. Multivariate analysis 
revealed that PET-CT staging independently predicted worse PFS and OS (52). 
Timing - The timing is very important in determining the accuracy of 18F-FDG PET-
CT, as RT-induced inflammation of the mucosal tissues surrounding the tumour could 
hinder the interpretation of images in both the early and late phases of treatment. The 
best timing to evaluate tumour response during RT in HNSCC patients is not yet 
defined, because a significant increase in FDG uptake early (within the third week of 
CRT) in the treatment due to inflammatory reactions and repair processes has been 
reported (76). For the purpose of RT replanning, Hentschel et al (77) suggested that 
therapy-associated inflammation of the mucosal tissue surrounding the tumour limits 
the proper definition of tumour volume mainly from the third week of concomitant 
CRT. They also found that whereas the median SUVmax decreased, the median 
values of gross tumour volume delineated on the PET images and metabolic tumour 
volume seemed to increase during RT. 
The timing of a post-RT PET-CT is often debated, and different protocols have been 
studied, particularly regarding neck node response to treatment (78). A PET-CT scan 
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after 12 weeks post-RT was shown to be dependable when neck node response was 
assessed (79). Full effect following RT must be allowed before therapy evaluation; on 
the contrary, should a salvage treatment be required this should be performed without 
unnecessary delay. Therefore, the ideal timing of PET-CT is debated since fulfilment 
of both criteria is necessary. 
The PET-NECK trial found that PET-CT–guided surveillance resulted in fewer neck 
dissections than did planned dissection surgery (54 vs. 221); the rates of surgical 
complications were similar in both the groups (42% and 38%, respectively). The 2-
year overall survival rate was 84.9% (95% confidence interval [CI], 80.7 to 89.1) in 
surveillance group and 81.5% (95% CI, 76.9 to 86.3) in planned-surgery group. The 
hazard ratio for death slightly favoured PET-CT–guided surveillance and indicated 
noninferiority (upper boundary of the 95% CI for the hazard ratio, <1.50; P = 0.004) 
(37). They came to a conclusion that neck lymph node dissection was only indicated 
when PET-CT presented an incomplete or equivocal response) to planned neck 
dissection in a total of 564 patients with locally advanced HNSCC (Stage N2 or N3 
disease), who underwent CRT for primary treatment (37). 
Ong et al. studied 65 patients (84 heminecks) after concurrent CRT. 18F-FDG PET-
CT was performed on all patients at least 8 weeks after the end of therapy. The 
standard of reference consisted of histopathology of neck dissection specimens or 
clinical and imaging follow-up. In this study, the sensitivity and specificity were 71% 
and 89%, respectively, with a positive predictive value (PPV) of 38% and a NPV of 
97%. All false-positive lymph nodes in neck dissection specimens showed either 
inflammation or granulomatous disease, which are well-known causes of increased 
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18F-FDG uptake in lymph nodes. Nevertheless, the fraction of false positive studies 
could be decreased from 27% to 10% when the neck was assessed by combined PET-
CT rather than by structural imaging alone, while maintaining a high NPV of 97%. 
The true value of post therapy 18F-FDG PET in patients treated with current RT or 
CRT is the high NPV. Many patients who might otherwise proceed to biopsy or 
planned ND can in fact be observed with clinical follow-up and periodic imaging 
studies (80).  
It is the consensus view of the multidisciplinary head and neck cancer team at 
Memorial Sloan-Kettering Cancer Centre that a dedicated neck CT scan 
with intravenous contrast material and 18F-FDG PET (potentially in a single imaging 
session) should be performed about 10–12 weeks after the end of therapy, unless it is 
felt that clinical management requires imaging earlier. This time point strikes a 
balance between the clinical desire for early, yet accurate, response assessment and 
the surgeon’s desire not to unnecessarily perform a neck dissection on tissues in which 
extensive fibrosis and scar tissue have developed as the result of CRT. 
Shrinkage of large nodal masses will take time; early imaging after the end of therapy 
will only cause uncertainty and will rarely provide guidance for management (38). 
18F-FDG-PET-CT could have a potential interesting role in patients’ follow-up with 
HNSCC. In spite of that, the clinical advantages and economic costs of this issue have 
not yet been largely addressed. One of the largest studies has been published by a 
group from Pittsburg (75). They retrospectively evaluated 388 patients to assess the 
recurrence rate after radical CRT among patients who underwent PET-CT 
surveillance. Tumour recurrence was detected in 110 patients (73 asymptomatic and 
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37 symptomatic). Indeed, 95% (95% CI, 87–98%) of asymptomatic recurrences were 
observed within 2 years of follow-up. The authors wanted to evaluate patients for 
recurrence with PET-CT at 2, 5, 8- and 14-months post-treatment as their study 
demonstrated that PET-CT detected almost all HNSCC recurrences within 2 years. 
 
 
6. Effect of SUV 
Two meta-analyses were conducted to estimate the effect of SUV on the prognosis of 
HNSCC. First, Zhang et al (81) evaluated the potential of SUV [SUVmax and mean 
SUV (SUVmean)] as a prognostic marker. They concluded that increased 
SUVmax/mean of primary tumour is a poor prognosis factor and has a potential value 
in predicting local tumour control, disease-free survival and overall survival. 
Thereafter, Xie et al (82) did another meta-analysis to evaluate the prognostic value of 
SUV, confirming that low primary tumour SUV was linked with better survival 
prognosis. It should be noted that SUV estimates suffer from poor reproducibility 
between centres because there is lack of standardization of the acquisition and 
processing protocols. 
In a study done by Hall-Edwards Radiotherapy Research Group, UK (83), the overall 
PPV of PET-CT was low but was found higher for nodal recurrence compared with 
primary site recurrence. The PPV of a PET-CT with SUVmax > 6 was 100% for nodal 
disease and 92% for primary disease with SUVmax > 8. They found that these results 
could contribute to developing risk-stratified follow-up schedules. Further assessment 
should be undergone by patients with an early positive PET-CT at the primary site due 
to the relatively low PPV and morbidity of salvage surgery. 
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7. Interpretation pitfalls 
A diversity of possible 18F-FDG-PET-CT interpretation pitfalls and artefacts can be 
observed on routine head and neck studies. Among the various causes, the most 
common interpretation pitfalls are caused by variable physiological FDG uptake in 
salivary glands, within Waldeyer’s ring, muscles or brown adipose fat (BAT) and by 
increased FDG uptake owing to inflammatory and infectious conditions, recent 
surgery, previous CRT, contralateral cranial nerve palsy and thyroid nodules with high 
glucose metabolism. Less often, lesions may be missed on PET-CT because of low 
FDG avidity, small lesion size or owing to low scanner resolution. Common artefacts 
seen in the head and neck area are related to metallic implants and dental hardware or 
may arise due to patient motion between the CT and the PET acquisition (84). 
The head and neck muscles often show physiological uptake. It is frequently possible 
to trace a linear uptake from origin to insertion on fused images. The factors that 
decrease muscular uptake such as talking, chewing and eating after the FDG injection 
must be avoided (85). 
 
False negative PET scans might be caused by various factors. There is a phenomenon 
called the partial volume effect wherein small tumours, 
approximately less than 5 mm, may not be consistently detected. It refers to two 
different camera related issues that cause underestimation of the activity of a small 
source – one is the limited spatial resolution and the other is image sampling 
technique. PET camera resolution is one of the main causes of the extent of this 
problem (86). 
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The type of tumour is also an issue. As examples, adenoid cystic carcinomas, well-
differentiated sarcomas, extranodal marginal zone lymphomas and also any type of 
necrotic tumour may not be FDG avid. 
If the malignant lesion is situated in the proximity of an area with high FDG 
accumulation like close to the brain or the tonsils the lesions might be overlooked or 
not visible (84). 
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IV. METHODOLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
 
 
A. Study design and setting 
The present study was retro-prospective analysis of nodal status of pre and post-RT 
PET-CT in patients diagnosed with HNSCC (n=45) from May 2013 - March 2018.  
 
 
Patients provided consent for the scans (but was under a waiver of informed consent 
approved for those in the retrospective series), and the study was approved by the 
Institutional Review Board.  
B. Inclusion criteria 
Patients with node positive SCC of the larynx, hypopharynx and oropharynx, planned 
for organ preservation therapy with curative intent, and with no prior neck surgery, 
were included in the study. Patients were only eligible if the neck nodes demonstrated 
hypermetabolism on the pre-RT PET scan. 
4 weeks 
later 
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C. Methods 
All 45 eligible patients (35 male, 10 female; mean age ± SD, 53 ± 13 years) 
underwent a pre-RT PET-CT scan before the start of RT. Another post-RT PET-CT 
scan was performed 12 weeks after completion of RT. Patients without a pre-RT PET-
CT study, without primary HNSCC, and with node negative scans were excluded. 
The median time from completion of RT to post-RT PET-CT was 92 days; 80% of the 
patients had their post-RT PET-CT scan between 77 and 147 days after therapy. 
The PET result helped in the decision regarding neck dissection versus observation. 
The multidisciplinary team ultimately decided whether patients with an equivocal 
post-RT PET-CT scan would undergo neck dissection or be scheduled for third PET 
(PET3) scan. The decision was based on a various prognostic factors including initial 
N classification, human papillomavirus (HPV)/p16-status if possible, performance 
status and also the post-RT clinical response. Clinical follow-up examinations were 
scheduled every 3 months during the first 2 years after either neck dissection or 
negative PET3, every 4 months in year 3 and every 6 months during the last 2 years of 
follow-up. 
PET imaging in accordance with our standard clinical PET protocol, the patients were 
injected intravenously with FDG 3.7 MBq/kg body weight to a maximum dose of 370 
MBq after a 4-6 hour fasting period. All patients were imaged with an integrated PET-
CT system (Siemens Biograph True Point 6). After a 45 min - 1-hour uptake period at 
rest, images were acquired for 2 minutes per bed position. At baseline and for follow-
up studies, the CT scan was acquired together with the PET scan. CT scans helped in 
attenuation correction and anatomical localization. 
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D. Image interpretation 
All PET scans were visually evaluated by nuclear medicine physicians regarding 
metabolic response (87).  
In this study two experienced readers, without prior knowledge of the clinical 
outcome, re-evaluated all patients regarding metabolic neck node response. Images 
were assessed and SUVmax levels obtained using Multimodality workplace (Siemens 
Syngo 2009B, VE36 A SL10P25 sMMWP SPO4). Metabolic responses were scored 
according to the Deauville score (88).  
Overall assessment is denoted by the overall score, which is the highest score among 
the scores for all the neck nodes. The Deauville scores are given in Table 1 together 
with the categories used in the present study. 
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Examples of corresponding PET images are shown in the following figures. If FDG 
uptake was seen in the neck nodes, the highest uptake was scored. 
 
 
 
 
 
 
Fig: 9 - 65/M with Carcinoma tongue, T4N2M0 with pre-RT PET showing bilateral 
level 2a with highest SUV of 7.85 and post RT PET after 12 weeks showing no 
nodal recurrence – DS 1 
 
 
Pre-RT 
PET-CT 
Post-RT 
PET-CT 
Post-RT 
PET-CT 
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Fig: 10 - 50/M with Carcinoma left oropharynx, T1N2bM0 with pre-RT 
PET showing left level 2, 3 nodes with highest SUV of 9.12 and post- RT 
PET after 12 weeks showing significant regression 
 
 
Fig: 11 - In the same patient, Post-RT PET showed left level 3 node with SUV of 
2.97 and when compared with mediastinal blood pool was found to have DS 2. 
Post-RT 
PET-CT 
Pre-RT 
PET-CT 
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 Fig: 13 - In the same patient, Post-RT PET showed right level 2 node with SUV of 
2.47 and when compared with mediastinal blood pool was found to have DS 3. 
Fig: 12 -  48/M with Carcinoma supraglottis, T3N2cM0 with pre-
RT PET showing right level 2a, 3 nodes with highest SUV of 21.45 
and post- RT PET after 16 weeks showing significant regression 
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Fig: 14 - 55/F with carcinoma right pyriform sinus, T3N0M0 with 
pre-RT PET showing right level 2, 3 nodes with highest SUV of 
9.68 and post- RT PET showing residual right level 3 node 
 
 
 
Fig: 15 - In the same patient, Post-RT PET showed right level 3 node with SUV of 5.63 
and was higher than mediastinal blood pool and liver and was found to have DS 4. 
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Fig: 16 - 51/M with carcinoma hypopharynx, T4N2aM0 with pre-
RT PET showing right level 2, 3 nodes with highest SUV of 26.78 
 
 
 
Fig: 17 - In the same patient, Post-RT PET showed right level 2, 3 
nodes with SUV of 15.27 and was found to have DS 5. 
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E. Definitions 
A complete response to RT in the neck and regional control (RC) was defined as no 
residual or recurrent tumour in the neck after completion of RT until the last date of 
follow-up in our institution. A residual tumour in the neck was categorized as 
persistent tumour, according to the pathology report, after neck dissection planned as a 
result of the post-RT PET or PET3 scan. The Deauville criteria Likert scale was 
dichotomized into responders (scores 2 and 3) and nonresponders (scores 4 and 5).  
A post-RT PET scan demonstrating a DS of 2 or 3 was considered true negative if the 
patient did not have any tumour on histopathological correlation after neck dissection, 
or any neck relapse during follow-up. In false-negative post-RT PET scans, either 
residual tumour was found or a relapse occurred during the follow-up period. Scans 
reported as showing DS of 4 or 5 were considered true-positive if neck dissection 
revealed residual tumour, according to the pathology report, or if there was 
progressive neck disease in patients with non-operable disease during the clinical 
follow-up. It would be considered false-positive on post-RT PET scans, if no residual 
tumour, according to the pathology report, was found in the neck dissection specimen. 
F. Statistical analysis 
Data were summarized using the mean (SD)/Median for continuous variables based 
on the normality. The categorical data were expressed as number and frequency. The 
change in SUV from pre-RT PET to post-RT PET was analysed using paired t-
test.  The association between the categorical data were analyzed using Fisher's exact 
test. The log-rank test was used to compare the categorical predictors over the 
recurrence. A p value of <0.05 was considered statistically significant. All the analysis 
were performed using STATA I/c 15 software.   
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V. RESULTS 
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A. Patient and tumour characteristics 
Forty-five patients (35 male and 10 female) who fulfilled the criteria were included in 
the given study period. 
Characteristic Value 
Age (years), median 
(range)  18-80, 54 
Gender  
Female  10 (22.2%) 
Male  35 (77.8%) 
Primary site (n=45)  
Nasopharynx 9 (20%) 
Tonsil  5 (11.1%) 
Oropharynx (other than 
above) 12 (26.7%) 
Hypopharynx 9 (20%) 
Larynx 10 (22.2%) 
T classification (n=45)  
T1 6 (13.3%) 
T2 8 (17.8%) 
T3 15 (33.3%) 
T4 16 (35.6%) 
N classification  
N0 11 (24.5%) 
N1 10 (22.2%) 
N2 22 (48.9%) 
N3 2 (4.4%) 
Treatment  
Radiotherapy 45 
Concurrent chemotherapy 43 
 
 
Table 2: Patient characteristics 
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Fifteen out of forty-five patients (33.3%) were under the age of 50 years and thirty out 
of forty-five patients (66.7%) were above the age of 50 years. 
Figure: 19 Age-wise distribution 
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The primary site of tumour was classified as nasopharynx (20%), tonsil (11.1%), 
oropharynx (26.7%), hypopharynx (20%) and larynx (22.2%). 
 
Figure: 20 Primary site 
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B. TNM Classification 
 
Figure: 21 T classification 
 
 
Figure: 22 N classification 
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Figure: 23 M classification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43
2
M classification
M0
M1
63 
 
C. Deauville Criteria Score 
Deauville score was assessed based on the nodal FDG activity of post RT-PET scans 
when compared with pre-RT-PET scans. It was compared with mediastinal, liver 
blood pool or both. Then it was categorised into the following groups: DS 1, DS 2-3 
and DS 4-5. DS 1 was found in 22 patients, DS 2-3 in 19 patients and DS 4-5 in 4 
patients. 
 
 
 
Figure: 24 Distribution of DEAUVILLE SCORE (DS) 
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Of the 22 patients in the DS-1 group, the SUVmax levels of the most active neck node 
in pre-RT PET scans were ranging from 2.6-23.72 (median SUVmax 8.8) and the 
neck nodes did not show any FDG activity in their respective post-RT PET scans. 
Of the 10 patients in the DS-2 group, SUVmax levels of the most active neck node in 
pre-RT PET scans of DS-2 group were ranging from 2.5-21.1 (median SUVmax 7.9) 
and as compared to SUVmax levels measured in their respective post-RT PET scans 
were ranging from 1.83-2.97 (median SUVmax 2.27). Using Wilcoxon signed-rank 
test, the p-value was found to be 0.0051 while comparing pre and post-RT SUVmax 
levels showing that RT/CRT had significantly reduced the SUVmax levels of the 
nodes. 
 
Figure: 25 Comparison of pre and post RT PET SUVmax in DS 2 
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Of the 9 patients in the DS-3 group, SUVmax levels of the most active neck node in 
pre-RT PET scans were ranging from 2.7-21.45 (median SUVmax 5.3) and as 
compared to SUVmax levels measured in their respective post-RT PET scans were 
ranging from 2.42-3.65 (median SUVmax 3.06). Three out of these nine patients had 
histopathologically confirmed residual tumour cells on follow-up. Using Wilcoxon 
signed-rank test, the p-value was found to be 0.01 while comparing pre and post-RT 
SUVmax levels showing that RT/CRT had significantly reduced the SUVmax levels 
of the nodes in this group. 
 
 
 
Figure: 26 Comparison of pre and post RT PET SUVmax in DS 3 
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Of the 4 patients in the DS 4-5 group, SUVmax levels of the most active neck node in 
pre-RT PET scans were ranging from 6.69-28.26 (median SUVmax 18.23) and as 
compared to SUVmax levels measured in their respective post-RT PET scans were 
ranging from 5.63-15.27 (median SUVmax 10.13) and all of them had disease 
progression. The number of patients was too small to allow a reliable calculation for 
p-value for comparing the effect of RT on pre and post-RT SUVmax levels. 
 
 
Figure: 27 Comparison of pre and post RT PET SUVmax in DS 4-5 
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progression was confirmed in 5 (71.4%) patients by tissue diagnosis and 2 (38.6%) 
patients by imaging and clinical follow-up. They were all in DS 3-5 groups. 
There was no disease progression in DS 1-2 groups. 
It was found that 38/41 patients with DS 1-3 had no nodal recurrence showing a high 
NPV of 93%. Of the 4 patients with DS 4-5 all had active disease showing PPV of 
100%. 
Applying Fisher’s exact test, the p-value was found to be 0.004. This highlighted that 
DS 2-3 was useful in predicting absence of nodal recurrence and DS 4-5 in predicting 
disease progression. 
  DS 2 
 
DS 3 DS 4-5 Total 
No nodal 
recurrence 10 
 
6 0 16 
Disease 
progression 0 
 
3 4 7 
Total 10 9 4 23 
 
 
  
Table 3 – Follow up in DS groups 2-5 
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VI. DISCUSSION 
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As there are 680,000 new HNSCC cases in the world per year it was imperative that 
there was development of functional imaging like F-18 FDG PET-CT and it was also 
endorsed by the current NCCN guidelines for diagnosis and staging. This was because 
18F-FDG PET-CT can identify an occult primary tumour and is very accurate in 
detecting metastases or second primary tumours elsewhere in the body, and precise 
delineation of target volumes is critical for IMRT treatments.  
The response of HNSCC to treatment depends on various factors such as clinical 
history (previous treatments), tumour characteristics (stage and biology), surrounding 
microenvironment and host immunoresponse.  
It has been well-known that 18F-FDG PET-CT is a powerful predictor in the 
assessment of the response after CRT or RT alone. The pre-eminence of functional 
over conventional imaging in response evaluation consists of its ability to 
semiquantitatively assess glucose uptake as a cancer cell viability indicator. 
Early identification of poor responders or nonresponders may allow modification of 
the treatment plan (volume and doses) and/or implementation of alternative 
therapeutic strategies to intensify treatment. Therefore, utilising a Likert scale such as 
DS which could categorise the responders from non–responders, would prevent 
unnecessary prophylactic neck dissections.  
In this study there was a good concordance between the DS and SUVmax. All 
methods of assessment predicted RC with high significance and almost similar to each 
other. The D also showed encouraging results in discriminating responders from 
nonresponders on PET scans judged as equivocal. SUVmax is an estimation of tumour 
metabolic activity and also the most commonly used SUVmax parameter in PET-CT 
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(29). It is a single-voxel value unfavourably affected by noise (31) and need not 
necessarily reflect the metabolic activity of the tumour as a whole. There was 
significant difference in SUVmax between patients with and without 
residual/recurrent tumour after completion of RT in DS 2-3 groups only. 
Nevertheless, measurement of SUVmax is affected by technical, biological and 
physical factors (30), and in spite of an attempt to establish common criteria there are 
still many diverse ways of calculating and presenting SUVmax. Published cut-off 
values are usually specific to the method and to the institution (29). In this study, as 
also shown previously, SUVmax did not give any additional value when compared 
with visual inspection in the clinical setting (80,89). 
Anderson et. al, concentrated on a triphasic delayed measurement of SUVmax with 
the main intent of reducing the number of false-positive and equivocal scans after RT 
(90). They found different FDG kinetics in inflammatory lesions compared with 
residual tumour 12 weeks after therapy completion and were able to improve the PPV. 
One advantage of the dynamic PET study would be that each patient served as his or 
her own control, which would reduce inter-institutional variations. 
Treatment response is an important factor for planning management and determining 
prognosis in HNSCC. Clinical examination, conventional imaging methods such as 
CT and MR imaging, and histopathology examination done after endoscopy are 
generally used options for therapy response assessment. Nevertheless, these methods 
have been reported to have variable diagnostic accuracy (91,92). It has been 
established that PET-CT has great potential to predict treatment response and helps in 
the early detection of residual or recurrent disease, which allows salvage therapy to be 
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implemented and helps in predicting complete response, avoiding the need for 
unnecessary intervention (93,94). Known limitations also include low PPVs, ascribed 
to inflammation and post-treatment effects, such as edema, fibrosis, asymmetry, and 
anatomic distortion. The high NPVs observed in these studies indicate that a negative 
post-treatment scan is suggestive of absence of active disease, thereby influencing 
treatment planning (95). 
There is so far a need for consensus on qualitative assessment and reporting of PET 
scan results. There has been no established interpretation system described in the 
literature to help readers classify the post-treatment PET-CT findings in a reliable 
manner in patients with HNSCC. There have been multicentre trials in Hodgkin 
lymphoma where the DS has been validated and approved (33,88,96). In 48 patients 
with HNSCC using routine clinical follow-up as the reference, Krabbe et al. used a 
five-point scale in a serial PET evaluation, 3, 6, 9 and 12 months after treatment and 
demonstrated an overall PPV of 51 % and a NPV of 100 % (97). Marcus et al. in 2014 
introduced and validated the Hopkins criteria, a five-point Likert scale which is very 
similar to DS (34). 
In a prospective PET study done by Porceddu et al. qualitative interpretation on focal 
uptake was assessed in relation to uptake in adjacent tissue and the liver (79). There 
were three different categories: “positive” (for residual tumour), “negative” and 
“equivocal”. NPV was found to be as high as 97.1 % in the long-term follow-up even 
though all recurrences, irrespective of when they occurred, were included in the 
“false-negative” group (12). As mentioned above, the NPV of DS used in this study 
was 93%. This may be due to the fact that the studies were scheduled 12 weeks after 
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RT. Higher accuracy of PET scans have been noted in recent studies and meta-
analyses, where it was scheduled later than 7 weeks after treatment (98,99). The 
treatment regimens were not uniform. In our setting, single modality treatment with 
RT was rarely used and CRT was used in >95 % of the patients which aligned with 
similar studies in which CRT is more frequent. In this study the PET results were 
characterized as false-negative if recurrent cancer was found at any stage during the 
follow-up period in contrast to the studies by Krabbe et al. and Marcus et al. in which 
a 6-month limit for false-negative scans was applied (34,48). 
Post-RT PET-CT scan with DS 1 was defined as “no FDG uptake”, which is a 
category of limited clinical value. A likely cause of no FDG uptake could be complete 
necrosis of the neck node.  
The benefit of adding DS to the PET report is apparent as responses can be 
categorized, and are distinct and easily interpreted by the oncologist or head and neck 
surgeon who have to act upon the PET result. In the present study, 42.22% (19 of 45 
post-RT PET-CT scans) were in DS 2-3 group.  The percentage of equivocal scans is 
higher than that found in previous studies (100). By considering the equivocal PET 
scans together with those scored as 2 or 3 (responders), we were able to correctly 
categorize 16 of the 19 patients. In three remaining patients, categorized in DS 2-3 
group, we diagnosed recurrences greater than 5 months after therapy completion. The 
group of PET scans assessed as equivocal was small and statistics should be 
interpreted with caution.  
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However, DS adequately categorized 84.2 % of the equivocal PET scans, which is 
encouraging. In the group of PET scans judged as equivocal, SUVmax provided no 
additional predictive value. 
In this study we chose to focus on the neck nodes with the highest FDG uptake in 
relation to treatment response. We did not evaluate the primary site response but it 
would be of interest to investigate whether using DS could minimize the number of 
equivocal scans here as well (101).  
The study results need to be interpreted within the context of this study. HPV status 
was not available for all the patients in the study, especially earlier in the study period. 
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VII. LIMITATIONS OF THE STUDY 
 
 
This is a retro-prospective analysis restricted by a small sample size conducted 
in a single institution. All equivocal scans did not have histopathological 
confirmation of residual tumour. All the patients did not have post-treatment 
histopathological confirmation as reference. 
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VIII. CONCLUSION 
Equivocal PET scan in HNSCC poses clinical dilemma. DS based on Likert 
scale for assessment of FDG metabolism in neck nodes following organ 
preservation therapy in HNSCC is a promising tool to overcome this problem. 
All patients with DS 4 or 5 on post-treatment PET scan can be considered as 
non-responders and should be routinely scheduled for neck dissection.  
Deauville score seems to satisfy the requirements for a simple qualitative 
method of interpreting PET scans and for identifying patients requiring neck 
dissection. Consensus regarding qualitative assessment would facilitate 
standardisation of PET reporting in clinical practice and enable comparative 
multicentric studies. 
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Appendix 1 - Informed Consent form to participate in a research study 
Study Title: 18F-FDG PET-CT response evaluation in head and neck malignancy.  
Study Number: ____________  
Subject’s Initials: __________________ Subject’s Name: _________________________________________  
Date of Birth / Age: ___________________________  (Subject) 
 i) I confirm that I have read and understood the information sheet dated ____________  
( for the above study and have had the opportunity to ask questions. [  ]  
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being affected. 
[  ] (iii) I understand that doctors in CMC, the Ethics Committee and the regulatory authorities 
will not need my permission to look at my health records both in respect of the current study 
and any further research that may be conducted in relation to it, even if I withdraw from the 
trial. I agree to this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published. [  ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [  ] 
(v) I voluntarily agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
 
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
 
Or 
 
 
 
 
 
 
 
 
Representative: _________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
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Appendix 2 - INFORMATION SHEET FOR INFORMED CONSENT 
 
Study Title: PET-CT response evaluation in head and neck malignancy. 
 
You are requested to participate in a study to assess the usefulness of grading responses to 
RT using PET-CT in head and neck squamous cell carcinoma (HNSCC). The final conclusion 
will be made after comparing the completion of the study.  
 
What is a PET-CT scan? PET-CT combines two types of scans into one: a PET (positron 
emission tomography) scan shows  the rate at which your body’s cells break down sugar 
and use it (also called metabolism), and a CT (computed tomography) scan shows your 
body’s organs, bones, and tissues in greater detail than  regular x-rays. This PET-CT 
combination lets doctors get 3D images of the inside of your body using one scanner. When 
a CT scan is placed on top of a PET scan, doctors can find the exact area of  abnormal cell 
activity. Most PET-CT scans call for an intravenous (IV) injection of a radiolabeled  sugar 
(sugar that is mixed with a radioactive tracer), which will move through your body. This 
sugar will be metabolized or used by the cells and organs. Some cells and many diseases use 
sugar more than others, and a PET-CT scan can actually measure these differences.  
 
Does this study have any side effects? The radioactive tracer used in the study will not cause 
any side effects. 
 
If you take part what will you have to do?  
If you agree to participate in this study, you will undergo at least 2 PET-CT scans, one before 
the treatment and one 12 weeks after RT, as part of your routine workup and management. 
There will be no change in the other treatment and investigations which are advised by 
your doctor. No blood tests will be required for this study.  
 
Will you have to pay for the PET-CT study? As it is a part of the routine workup and 
management of the HNSCC , the patient is expected to pay for his/her own study. 
 
What happens after the study is over?  The final results of this study will interpreted at the 
end of  2 years. If we come to a conclusion that the study is beneficial, we will be able to use 
this information and help increase the utility of grading response to RT in HNSCC which will 
further help the clinician to keep the patient on routine follow-up or have a close 
monitoring of the patient. 
 
Will your personal details be kept confidential? The results of this study will be published in 
a medical journal, but your identity will not be revealed in any manner. However, the 
images may be reviewed by other specialists associated with the study without your 
additional permission.  
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Appendix 3 
            18F- FDG PET-CT response evaluation in head and neck malignancy                   
 Proforma 
 
Date of entry : 
ID No.  : 
Name  :    Age :  Hospital No. : 
Diagnosis : 
                                                                                    PET 1 
DATE  
INVOLVED NECK NODAL 
STATIONS 
 
HIGHEST SUV  
 
                                                                          RT AFTER PET 1 
DATE  
DURATION  
TYPE  
 
                                                                                    PET 2 
DATE  
INVOLVED NECK NODAL 
STATIONS 
 
HIGHEST SUV  
DEAUVILLE SCORE  
 
                                                                          RT AFTER   PET 2 (If applicable) 
DATE  
DURATION  
TYPE  
 
Other treatment: 
 
 
                                                                     PET 3 IF APPLICABLE 
DATE  
INVOLVED NECK NODAL 
STATIONS 
 
HIGHEST SUV  
DEAUVILLE SCORE  
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Appendix 6 – Data Set 
 
 
 
Sl. No. Sl. No. Age Gender Hospital no. Diagnosis T N M
Date of PET 1 Neck nodes Highest SUVF/u Days Date of PET 2Neck nodes Highest SUV DS F/u
1 1 43 M 773701F 1 2 2 0 07-03-2014 Bilateral level 2-5 13.35 53 47 23-06-2014 Nil 1 1
2 2 24 M 690038G 1 3 2 0 28-09-2016 Level 2, 3 16.9 23 140 18-04-2017 R level 2 1.95 1 1
3 3 53 M 835482F 1 2 2 1 28-04-2017 Level 2b 3.29 15 131 13-12-2017 R level 2b 2.24 1 1
4 4 54 M 234058G 3 4 0 0 23-06-2015 R level 2, 3 8.39 38 54 13-11-2015 Nil 1 1
5 5 64 M 762762G 5 3 0 0 13-03-2017 Level 3 2.5 17 69 26-07-2017 L level 3 2.21 1 1
6 6 55 M 832101G 5 4 2 0 12-04-2017 Level 2, 3, PaPx 4.01 16 92 07-09-2017 level 2,3 2.83 2 1
7 7 57 M 928837G 5 3 0 0 17-08-2017 Level 2a, 2b 4.48 12 126 19-01-2018 Nil 1 1
8 8 52 M 948113G 5 2 2 0 16-08-2017 Level 2, 3 10.89 12 114 03-01-2018 Nil 1 1
9 9 48 M 804236G 5 3 2 0 17-03-2017 Level 2a, 3, 4 21.45 16 125 06-10-2017 R level 2 2.47 1 1
10 10 46 M 916433G 3 4 1 0 25-07-2017 Level 2, 3 28.26 13 160 07-03-2018 Level 2 12.42 4 2
11 11 77 F 890754G 5 2 2 0 12-06-2017 Level 2, 3, 4 17.45 14 81 26-10-2017 Nil 1 1
12 12 69 F 034350H 2 3 1 0 17-11-2017 Level 2 12.88 9 88 17-04-2018 Nil 1 1
13 13 56 M 553739G 4 4 2 0 01-05-2017 R level 2a, retroPx 13.34 16 92 22-09-2017 R lvl 2a, retroPx 1.83 1 1
14 14 55 M 991110G 2 2 1 0 10-01-2018 L level 2a 2.7 7 76 14-06-2018 L level 2a 2.42 1 1
15 15 55 F 038589H 4 3 0 0 24-11-2017 Level 1b, 2, 3 9.68 9 93 02-05-2018 Level 2, 3 5.63 4 2
16 16 50 M 048746H 3 1 2 0 28-11-2017 Level 2, 3, 4, L SCL 9.12 9 95 04-05-2018 L level 3 2.97 1 1
17 17 54 M 031161H 5 3 0 0 29-11-2017 L Level 2a 4.45 9 118 25-05-2018 L Level 2a 2.75 1 1
18 18 57 M 050416H 4 4 2 0 26-12-2017 Level 2a, 3, 4 23.72 8 92 16-05-2018 Nil 1 1
19 19 62 M 057356H 5 3 0 0 15-12-2017 L Lvl 2a, 5, R Lvl 3 8.45 8 91 16-05-2018 Nil 1 1
20 20 18 M 980761G 1 3 2 0 26-09-2017 Bilateral level 2b 15.31 8 93 31-05-2018 Nil 1 1
21 21 70 M 160439B 3 4 2 0 27-11-2017 Level 2a, 3, 5 6.74 9 80 09-04-2018 R level 2 3.06 1 1
22 22 43 M 984150G 2 4 2 1 05-09-2017 Level 2a, 2b, PaPx 21.97 8 93 31-05-2018 Nil 1 1
23 23 29 F 401366G 1 4 3 0 27-04-2016 Level 2a, 2b 2.64 11 99 19-02-2018 Nil 1 1
24 24 52 M 085613H 3 4 1 0 03-01-2018 L level 3 6.18 27 101 13-10-2016 Nil 1 1
25 25 64 M 303890C 3 1 0 0 27-02-2017 R lvl 1b, bil level2 8.3 16 80 06-09-2017 R level 2a, 1b 3.42 5 2
26 26 48 F 047084H 2 2 2 0 17-01-2018 Level 2a, 3 21.1 7 90 14-06-2018 R level 2 2.31 2 1
27 27 58 M 100325H 5 3 0 0 31-01-2018 Right level 3 3.3 7 81 19-06-2018 Nil 1 1
28 28 74 F 118047H 3 4 2 0 21-02-2018 Level 2a, 2b 9.15 6 77 06-07-2018 Nil 1 1
29 29 64 M 045380H 4 3 0 0 20-12-2017 L cervical 2.83 8 131 02-07-2018 L cervical 2.16 1 1
30 30 36 F 261074G 1 1 1 0 21-07-2015 R level 2b, 3 10.92 36 165 16-03-2016 Nil 1 1
31 31 63 M 077622G 1 3 1 0 22-12-2014 L level 2a 2.6 43 364 10-03-2016 Nil 1 1
32 32 61 M 020880G 4 1 1 0 01-09-2014 R level 2a 6.69 47 220 23-06-2015 R level 2, 3 7.85 5 2
33 33 52 M 205318 3 4 0 0 10-11-2015 Bilateral 2a 4.34 33 140 03-06-2016 Bil level 2 3.65 3 2
34 34 37 F 426992D 4 2 1 0 11-07-2014 Bil level 2a, R lvl 3 4.31 49 84 03-12-2014 Nil 1 1
35 35 51 M 462908F 4 4 2 0 07-05-2013 R level 2,3 26.78 53 147 15-12-2014 Level 2a,3 15.27 5 2
36 36 59 F 015731G 4 4 2 0 22-09-2014 L level 3 3.08 47 369 17-11-2015 R level 2 3.3 3 2
37 37 51 M 272401G 3 1 2 0 24-07-2015 Bilateral level 2a 5.33 35 106 19-02-2016 L level 2a 3.41 3 1
38 38 65 M 687582G 3 4 2 0 13-02-2017 Bil level 2a, L lvl 5 7.85 18 88 18-07-2017 Nil 1 1
39 39 80 F 907200G 2 2 2 0 10-07-2017 R level 2, 3 10.28 13 110 02-01-2018 R level 2, 3 2.3 1 1
40 40 47 M 940897G 1 4 1 0 27-07-2017 Bil lvl 2a, retropx 11.4 12 129 19-03-2018 Nil 1 1
41 41 48 M 927890G 1 3 3 0 24-08-2017 Bilateral level 2 16.58 9 91 16-04-2018 Nil 1 1
42 42 59 M 989849G 3 4 2 0 27-10-2017 L level 2a 4.03 9 91 06-04-2018 Nil 1 1
43 43 30 M 711016D 3 3 1 0 14-02-2018 R level 2, 3 6.73 6 92 20-07-2018 R level 2 2.35 1 1
44 44 63 M 117728H 4 1 0 0 14-03-2018 Bil Level 2b 7.36 5 83 02-08-2018 Nil 1 1
45 45 42 M 896078 5 3 2 0 15-03-2018 R level 2a, 2b 14.68 4 76 22-08-2018 R level 2b 2.51 1 1
Coding for Diagnosis Coding
Napx 1 1 - No nodal recurrence
Tonsil 2 2 - Disease progression
Oropharynx 3
Hypopharynx 4
Larynx 5
PET 1 RT PET 2
